ERBB2 and breast cancer: To further validate the effects of LINC00899 and miR-425 in patients with TNBC, plasma exosomes were collected from 119 patients with breast cancer treated with neoadjuvant chemotherapy (59 patients with TNBC, 32 with HER2+-type and 28 with luminal-type) and 20 healthy women.